(MRK) Merck & Co., Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(MRK) Merck & Co., Inc. Bundle
See the Bigger Picture
This Merck & Co., Inc. BCG Matrix helps you quickly see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio planning. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Keytruda 2024 sales $29.5B
Keytruda generated $29.5 billion in 2024 sales, making it Merck & Co., Inc.'s largest brand and the top PD-1 therapy globally. Its use keeps widening across tumor types and earlier treatment lines, including lung, melanoma, and adjuvant settings. With very high share and still-strong growth, Keytruda fits the Star box in Merck & Co., Inc.'s BCG Matrix.
Gardasil 9 2024 sales $8.6B
Gardasil 9 delivered $8.6B in 2024 sales, making it one of Merck & Co., Inc.’s biggest growth engines. The HPV vaccine still has strong demand in adolescent and adult programs across key markets, even with regional swings. With high share in a growing preventive-care market, it fits the Stars quadrant in the BCG Matrix.
Bravecto flea and tick franchise
Bravecto is a top companion-animal parasiticide brand, with 12-week protection that supports repeat use and better compliance. Pet ownership and preventive care keep demand high, and longer treatment cycles help lift refill value. In a large, durable animal-health category, Merck & Co., Inc. can still treat Bravecto as a Star.
Nobivac companion animal vaccines
Nobivac is a core brand in Merck Animal Health’s vaccine lineup, and that fits a Stars position because pet vaccines are tied to repeat vet visits and booster cycles. Companion-animal vaccine demand stays structurally firm as pet care spend keeps rising, and Nobivac’s wide veterinary channel reach supports share retention.
- Core portfolio brand
- Recurring booster demand
- Strong vet channel presence
- Fits a growth market
Allflex senseHub digital animal health
Allflex senseHub fits Stars: Merck Animal Health said the unit generated about $5.8 billion in 2024 sales, and its digital tags and monitoring tools help farmers track animals, cut losses, and improve herd decisions.
Livestock tech spend is rising as producers chase better yield and tighter biosecurity; precision livestock farming demand is growing fast, and connected sensors are moving from niche to core farm tools.
The business has real momentum in a fast-growing niche, with traceability rules and herd-health pressure making digital ID a must-have, not a nice-to-have.
- About $5.8B Animal Health sales in 2024
- Supports traceability and herd control
- Demand rises with biosecurity needs
Merck’s Star Brands: Keytruda and Gardasil 9 Lead the Way
Keytruda and Gardasil 9 are Merck & Co., Inc.'s clearest Stars: they combine top market share with strong growth, led by 2024 sales of $29.5B and $8.6B. Bravecto, Nobivac, and Allflex senseHub add recurring demand from pets, livestock, and farm tech. These brands sit in growing segments with durable customer use.
| Brand | 2024 Sales | Star Signal |
|---|---|---|
| Keytruda | $29.5B | Global PD-1 leader |
| Gardasil 9 | $8.6B | High share, growth |
What is included in the product
Detailed Word Document
Merck & Co. BCG Matrix: clear, quadrant-by-quadrant view of growth, cash, and divestment priorities.
Editable Excel File
Merck & Co., Inc. BCG Matrix, a quick view to pinpoint winners and laggards at a glance
Reference Sources
Provides a traceable source trail for Merck & Co., Inc., boosting credibility and helping investors verify key assumptions fast.
Cash Cows
Bridion anesthesia reversal franchise
Merck & Co., Inc. reported Bridion sales of about $1.5 billion in 2025, after roughly $1.3 billion in 2024, supported by steady hospital use in anesthesia reversal. Surgical volumes keep demand stable, but growth is not fast. Its strong market position and recurring cash flow make Bridion a clear Cash Cow.
Gardasil 9 mature cash generation
Gardasil 9 is still a cash machine for Merck & Co., Inc., with 2024 sales of about $8.6 billion and strong margins from global scale. Growth has cooled from the launch years, so the vaccine now looks more like a steady harvest than a high-growth push. High share, mature demand, and slower growth fit classic Cash Cow behavior.
M-M-R II legacy vaccine
M-M-R II is a long-established pediatric vaccine and a steady Merck cash cow. Demand stays tied to the routine 2-dose childhood immunization schedule, so volumes are predictable and low growth supports cash generation. With a strong franchise in a mature market, it fits the classic Cash Cow profile.
ProQuad childhood vaccine
ProQuad is a cash cow for Merck & Co., Inc.: a long-selling childhood vaccine with mature, recurring demand and little need for heavy promotion. Merck does not report ProQuad revenue separately, but the brand sits in a stable vaccine mix that supports steady cash flow more than fast growth. Its value comes from repeat immunization use, not market expansion.
- Stable demand
- Low promo spend
- Steady cash flow
- Mature market
Vaqta hepatitis A vaccine
Vaqta fits Merck & Co., Inc.'s Cash Cows bucket: hepatitis A is a mature preventive market, so demand is stable and growth is limited. Merck does not separately disclose Vaqta sales in its public filings, which suggests it is a small, steady contributor rather than a major growth engine.
- Steady, mature vaccine demand
- Useful for cash generation
- Not a main growth driver
That profile supports a low-investment, harvest-style strategy, with cash used to fund higher-growth assets like oncology and animal health. In BCG terms, Vaqta is a classic cash cow: predictable, defensible, and not built for rapid expansion.
Merck's Cash Cows Keep the Pipeline Funded
Merck & Co., Inc.'s Cash Cows are mature, high-share products that keep throwing off cash: Bridion delivered about $1.5 billion in 2025 sales, up from $1.3 billion in 2024, while Gardasil 9 brought in about $8.6 billion in 2024. M-M-R II, ProQuad, and Vaqta add stable, low-growth vaccine cash with limited promo spend. These products fund Merck & Co., Inc.'s R&D and higher-growth bets.
| Product | 2025/2024 sales | Cash Cow signal |
|---|---|---|
| Bridion | $1.5B / $1.3B | Steady hospital demand |
| Gardasil 9 | $8.6B | Mature, high-margin scale |
Preview the Actual Deliverable
Merck & Co., Inc. Reference Sources
You’re previewing the exact Merck & Co., Inc. BCG Matrix report you’ll receive after purchase. What you see here is the final, fully formatted document—no demo content or placeholders. Once purchased, the same file is delivered for immediate use in analysis, presentations, or planning.
Dogs
Januvia post patent erosion
Januvia is a Dog: after U.S. patent loss, generic sitagliptin hit the brand hard, and Merck’s branded share in DPP-4 diabetes therapy has kept falling. The diabetes market is still huge, but Januvia’s growth is flat to negative, and Merck’s 2024 sales for the franchise kept sliding as low-cost copies took volume. Low growth plus weak retained share fit the Dog box.
Janumet genericized diabetes franchise
Janumet sits in Merck & Co., Inc.'s patent-loss phase, and generic sitagliptin-metformin has kept pressure on branded demand. Merck & Co., Inc.'s diabetes franchise now has little strategic upside from this asset, since price and volume both erode after loss of exclusivity. That makes Janumet a clear Dog in the BCG Matrix: low growth, weak value retention, and minimal capital priority.
Singulair mature allergy brand
Singulair is a legacy respiratory and allergy brand; after U.S. patent loss in 2012, generics took over most montelukast use. With Merck’s branded share now small and the market mature, it fits Dogs in the BCG Matrix. The 2020 FDA boxed warning on serious neuropsychiatric events also caps growth and keeps pricing weak.
Zetia low share lipid product
Zetia is a mature, low-growth lipid brand in Merck & Co., Inc.'s 2025 portfolio. U.S. generic ezetimibe has largely taken the category, so pricing power and market share are weak. In BCG terms, it fits a "dog": limited growth, heavy competition, and little cash-generation value.
- Low-growth, mature lipid product
- Generic competition dominates
- Weak pricing power in 2025
- No longer a cash cow
Vytorin declining combination therapy
Vytorin is a mature legacy lipid-lowering product in Merck & Co., Inc.’s portfolio, but Merck no longer gives it a separate sales line in recent filings, which signals very small scale. In a business that posted $64.2 billion in 2024 revenue, Vytorin’s branded position is weak, growth is limited, and it fits the Dog box: low share, low growth.
- Legacy product, no separate 2025 disclosure.
- Weak brand power in a mature statin market.
- Low-growth, low-share Dog.
Merck’s Dogs: Patent Loss Leaves These Brands Behind
Januvia, Janumet, Singulair, Zetia, and Vytorin are Dogs because patent loss left them in slow or shrinking markets where generics now win most volume. In Merck & Co., Inc.’s 2024 $64.2 billion revenue base, these brands have weak share, weak pricing power, and little growth. That makes them low-priority assets with limited cash-upside.
| Brand | 2025/2026 read |
|---|---|
| Januvia | Generic sitagliptin erodes sales |
| Janumet | Post-LOE, low growth |
| Singulair | Generic-led, boxed warning |
Question Marks
Winrevair 2024 launch
Winrevair’s 2024 launch in pulmonary arterial hypertension fits a Question Mark: it entered a clinically important, growing niche, but Merck is still early in share build. In STELLAR, it cut pulmonary vascular resistance by 34.6% and lifted 6-minute walk distance by 40.8 meters, supporting demand. Merck is still spending heavily to drive adoption after the 2024 launch, so cash use stays high.
Capvaxive 2024 launch
Capvaxive, Merck’s 21-valent adult pneumococcal vaccine approved in 2024, targets a broad prevention market and fits a Question Mark in the BCG Matrix. Early uptake is still small versus the large U.S. adult base eligible for pneumococcal vaccination, so near-term returns remain uncertain even as the product has clear long-term upside.
Enflonsia 2025 RSV launch
Enflonsia entered the infant RSV prevention market in 2025, after FDA approval in June 2025, so Merck & Co., Inc. is still in the launch phase. RSV is a large, high-growth category, with the CDC estimating 58,000 to 80,000 hospitalizations each year in U.S. children under 5. But Enflonsia’s current share is still low, so the brand has high upside but weak present scale. That makes it a classic Question Mark in the BCG Matrix.
MK-0616 oral PCSK9 inhibitor
MK-0616 sits in a huge pool: cardiovascular disease causes about 20.5 million deaths a year worldwide, and LDL-C lowering is still a core prevention market. An oral PCSK9 inhibitor could be disruptive versus injected drugs, but Merck & Co., Inc. still has no sales here, so this is a clear high-upside Question Mark.
- Huge CVD market, but no revenue yet.
- Oral route could improve uptake.
- Still in development, so risk stays high.
- Needs proof on efficacy, safety, and access.
Tulisokibart pipeline asset
Tulisokibart targets immune-mediated diseases, a large market, but Merck & Co., Inc. has not yet shown commercial sales or share for this asset. With the business case still being proven, it fits the Question Mark box in the BCG Matrix. The key test is conversion from clinical promise to revenue.
- Large market, unproven share.
- No disclosed sales yet.
- Upside depends on adoption.
Merck’s Big Growth Bets Still Need to Prove Themselves
Merck & Co., Inc.’s Question Marks are growth bets with little or no current share: Winrevair, Capvaxive, Enflonsia, MK-0616, and tulisokibart. They sit in big markets, but most are still in launch or development, so revenue is low and spend stays high. The upside is real, but each asset still must prove adoption, safety, and pricing.
| Asset | Status | BCG fit |
|---|---|---|
| Winrevair | 2024 launch | Question Mark |
| Capvaxive | 2024 approval | Question Mark |
| Enflonsia | 2025 approval | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.